Clinical trial · Observational
Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases
A Radiomics Approach to Predict the Effect of Bevacizumab Plus Chemotherapy in Patients With Liver Metastases of Colorectal Cancer: A Prospective Multi-Centers Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Colorectal carcinoma with liver metastasis is one of the major problems bothering physicians worldwide. Bevacizumab combined with chemotherapy is the standard treatment recommended by several guidelines. Despite the high cost, a certain portion of patients couldn't benefit from this therapy. This study is aiming to find out the specific type of patients who would respond to bevacizumab by Radiomics approach, and evaluate the prediction value of this imaging model with clinical and genetic factors.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colon Cancer | Malignant Colon Neoplasm | CURATED_EXACT | 0.92 |
| Liver Metastases | — | UNRESOLVED | — |
| Rectal Cancer | Malignant Rectal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- estimated ORR
- timeFrame
- 6-8 weeks
Secondary outcomes (2)
- measure
- estimated PFS
- timeFrame
- 3 years
- measure
- estimated OS
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Colorectal carcinoma confirmed by pathological result. 2. Liver metastasis confirmed by imaging studies. 3. Treatment of bevacizumab combined with chemotherapy chosen by MDT team. 4. ECOG: 0-2. 5. Normal laboratory studies including liver\\renal\\bone marrow functions. 6. Expected lifespan more than 3 months. Exclusion Criteria: 1. Previous treatment of colorectal cancer with liver metastasis. 2. Diagnosed with other malignancies. 3. Couldn't finish the trial due to several reasons such as allergy to chemotherapy drugs\\pregnancy or lactation\\chronic heart disease\\unable to sustain further treatment.
References
Publications (0)
Data not yet available